(Q37993889)

26 August 2017

title

New therapies for chronic hepatitis C infection: a systematic review of evidence from clinical trials (English)

1 reference

26 August 2017

1 reference

1 reference

1 reference

1 reference

2

1 reference

26 August 2017

L Y Lee

1

1 reference

26 August 2017

T Wong

series ordinal

3

1 reference

26 August 2017

M Wilkinson

series ordinal

4

1 reference

26 August 2017

publication date

1 April 2012

1 reference

International Journal of Clinical Practice

26 August 2017

published in

1 reference

26 August 2017

volume

66

1 reference

26 August 2017

issue

4

1 reference

26 August 2017

page(s)

342-355

1 reference

Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2012.02895.X

Hepatitis C Virus NS2 Protein Contributes to Virus Particle Assembly via Opposing Epistatic Interactions with the E1-E2 Glycoprotein and NS3-NS4A Enzyme Complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2012.02895.X

Hepatitis C virus NS5A: tales of a promiscuous protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2012.02895.X

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2012.02895.X

Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2012.02895.X

Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2012.02895.X

Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in 'real world' patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2012.02895.X

Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2012.02895.X

Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2012.02895.X

Side effects of therapy for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2012.02895.X

Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2012.02895.X

Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2012.02895.X

IL28B and the Control of Hepatitis C Virus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2012.02895.X

Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2012.02895.X

Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2012.02895.X

Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2012.02895.X

Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2012.02895.X

An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2012.02895.X

Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2012.02895.X

Safety and efficacy of viramidine versus ribavirin in ViSER2: randomized, double-blind study in therapy-naive hepatitis C patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2012.02895.X

Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2012.02895.X

Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2012.02895.X

S-Adenosylmethionine and betaine correct hepatitis C virus induced inhibition of interferon signaling in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2012.02895.X

S-Adenosyl Methionine Improves Early Viral Responses and Interferon-Stimulated Gene Induction in Hepatitis C Nonresponders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2012.02895.X

Combination therapy with thymosin alpha1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2012.02895.X

Boceprevir for previously treated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2012.02895.X

Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2012.02895.X

Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2012.02895.X

R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2012.02895.X

Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2012.02895.X

Evaluation of VCH-759 monotherapy in hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2012.02895.X

10.1111/J.1742-1241.2012.02895.X

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference